NCT00092456View on ClinicalTrials.gov

Consistency Lots Vaccine Study (V260-009)

PHASE3CompletedINTERVENTIONAL
Enrollment

793

Participants

Timeline

Start Date

May 31, 2003

Primary Completion Date

August 31, 2004

Study Completion Date

August 31, 2004

Conditions
Rotavirus Infections
Interventions
BIOLOGICAL

rotavirus vaccine, live, oral, pentavalent

Three oral doses (\~8.81 X 10\^7 IU/Dose for Lot 1; \~8.01 X 10\^7 IU/Dose for Lot 2; and \~6.91 X 10\^7 IU/Dose for Lot 3) of RotaTeq™ (rotavirus vaccine, live, oral, pentavalent) administered at 3 separate visits scheduled 4 to 10 weeks (28 to 70 days) apart with up to 42 days of safety follow up after each vaccination

BIOLOGICAL

Placebo

"Placebo-matching RotaTeq™ administered at 3 separate visits scheduled 4 to 10~weeks (28 to 70 days) apart with up to 42 days of safety follow up after each vaccination"

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00092456 - Consistency Lots Vaccine Study (V260-009) | Biotech Hunter | Biotech Hunter